Download PDF
J Neurol Surg B Skull Base 2024; 85(05): 439-444
DOI: 10.1055/a-2096-1802
Original Article

DOTATATE PET Imaging in Olfactory Neuroblastoma and Association with SSTR Expression

Daniel E. Palmieri
1   University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States
,
Kent S. Tadokoro 
2   Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States
,
Benita Valappil
2   Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States
,
Theja Pakala
3   Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States
,
Ashok Muthukrishnan
3   Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States
,
Raja R. Seethala
4   Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States
,
Carl H. Snyderman 
2   Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Introduction Olfactory neuroblastoma (ONB), or esthesioneuroblastoma, is a rare neuroectodermal tumor of the nasal cavity and paranasal sinuses. Most of these tumors express somatostatin receptors (SSTRs), providing a potential target for radionuclide imaging with Ga-68 DOTATATE. However, this imaging modality has not been extensively studied in ONB.

Methods We conducted a retrospective chart review of 96 endoscopic endonasal skull base surgery cases for ONB performed at our institution between 2000 and 2021. Histo (H) scores were assigned to each tumor and normalized DOTATATE standardized uptake values (nSUVs) were measured as well.

Results Nine patients (5 males and 4 females) with ONB were ultimately included in the study. The average age of the patients was 50 years. All ONBs had a positive SSTR2 expression (H-score > 105; mean: 180). All ONBs showed DOTATATE avidity (mean nSUV for ONB: 6.7). However, there was no correlation between H-score and nSUV, with an r 2 of 0.24 (p = 0.18).

Conclusion Our study shows that SSTR2 expression is found in all ONBs with associated DOTATATE avidity, which may serve as a valuable imaging modality to monitor for recurrent and metastatic disease in ONB.

Keywords

olfactory neuroblastoma - esthesioneuroblastoma - DOTATATE - SSTR2 - PET Imaging


Publication History

Received: 16 March 2023

Accepted: 13 May 2023

Accepted Manuscript online:
19 May 2023

Article published online:
12 June 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Thompson LD. Olfactory neuroblastoma. Head Neck Pathol 2009; 3 (03) 252-259
    CrossrefPubMedGoogle Scholar
  • 2 Bell D, Hanna EY, Weber RS. et al. Neuroendocrine neoplasms of the sinonasal region. Head Neck 2016; 38 (Suppl. 01) E2259-E2266
    CrossrefPubMedGoogle Scholar
  • 3 Hyams VJ, Batsakis JG, Michaels L. Tumors of the Upper Respiratory Tract and Ear. Washington, DC: Armed Forces Institute of Pathology; 1988
    Google Scholar
  • 4 Dulguerov P, Allal AS, Calcaterra TC. Esthesioneuroblastoma: a meta-analysis and review. Lancet Oncol 2001; 2 (11) 683-690
    CrossrefPubMedGoogle Scholar
  • 5 Tajudeen BA, Arshi A, Suh JD. et al. Esthesioneuroblastoma: an update on the UCLA experience, 2002-2013. J Neurol Surg B Skull Base 2015; 76 (01) 43-49
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Kuan EC, Nasser HB, Carey RM. et al. A population-based analysis of nodal metastases in esthesioneuroblastomas of the sinonasal tract. Laryngoscope 2019; 129 (05) 1025-1029
    CrossrefPubMedGoogle Scholar
  • 7 Peacock JG, Harmsen WS, Link MJ. et al. Risk of delayed lymph node metastasis in clinically N0 esthesioneuroblastoma. J Neurol Surg B Skull Base 2017; 78 (01) 68-74
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Fujioka T, Toriihara A, Kubota K. et al. Long-term follow-up using 18F-FDG PET/CT for postoperative olfactory neuroblastoma. Nucl Med Commun 2014; 35 (08) 857-863
    CrossrefPubMedGoogle Scholar
  • 9 Patel YC, Greenwood M, Kent G, Panetta R, Srikant CB. Multiple gene transcripts of the somatostatin receptor SSTR2: tissue selective distribution and cAMP regulation. Biochem Biophys Res Commun 1993; 192 (01) 288-294
    CrossrefPubMedGoogle Scholar
  • 10 Qian ZR, Li T, Ter-Minassian M. et al. Association between somatostatin receptor expression and clinical outcomes in neuroendocrine tumors. Pancreas 2016; 45 (10) 1386-1393
    CrossrefPubMedGoogle Scholar
  • 11 Cracolici V, Wang EW, Gardner PA. et al. SSTR2 expression in olfactory neuroblastoma: clinical and therapeutic implications. Head Neck Pathol 2021; 15 (04) 1185-1191
    CrossrefPubMedGoogle Scholar
  • 12 Dadgar H, Norouzbeigi N, Ahmadzadehfar H, Assadi M. 68Ga-DOTATATE and 18F-FDG PET/CT for the management of esthesioneuroblastoma of the sphenoclival region. Clin Nucl Med 2020; 45 (08) e363-e364
    CrossrefPubMedGoogle Scholar
  • 13 Hasan OK, Ravi Kumar AS, Kong G. et al. Efficacy of peptide receptor radionuclide therapy for esthesioneuroblastoma. J Nucl Med 2020; 61 (09) 1326-1330
    CrossrefPubMedGoogle Scholar
  • 14 Schneider JR, Shatzkes DR, Scharf SC. et al. Neuroradiological and neuropathological changes after 177lu-octreotate peptide receptor radionuclide therapy of refractory esthesioneuroblastoma. Oper Neurosurg (Hagerstown) 2018; 15 (06) 100-109
    CrossrefPubMedGoogle Scholar
  • 15 Ambrosini V, Kunikowska J, Baudin E. et al. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur J Cancer 2021; 146: 56-73
    CrossrefPubMedGoogle Scholar
  • 16 Lechner M, Takahashi Y, Turri-Zanoni M. et al. Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma. Eur J Cancer 2022; 162: 221-236
    CrossrefPubMedGoogle Scholar
  • 17 Ow TJ, Hanna EY, Roberts DB. et al. Optimization of long-term outcomes for patients with esthesioneuroblastoma. Head Neck 2014; 36 (04) 524-530
    CrossrefPubMedGoogle Scholar
  • 18 Zhang L, Vines DC, Scollard DA. et al. Correlation of somatostatin receptor-2 expression with gallium-68-DOTA-TATE uptake in neuroblastoma xenograft models. Contrast Media Mol Imaging 2017; 2017: 9481276
    CrossrefPubMedGoogle Scholar
  • 19 Yu J, Cao F, Zhao X. et al. Correlation and comparison of somatostatin receptor type 2 immunohistochemical scoring systems with 68Ga-DOTATATE positron emission tomography/computed tomography imaging in gastroenteropancreatic neuroendocrine neoplasms. Neuroendocrinology 2021
    PubMedGoogle Scholar